Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ocular Therapeutix (OCUL) Receivables - Other (2017)

Ocular Therapeutix has reported Receivables - Other over the past 3 years, most recently at $688000.0 for Q1 2017.

  • For Q1 2017, Receivables - Other changed N/A year-over-year to $688000.0; the TTM value through Mar 2017 reached $688000.0, changed N/A, while the annual FY2013 figure was $19000.0, N/A changed from the prior year.
  • Receivables - Other for Q1 2017 was $688000.0 at Ocular Therapeutix, up from $1000.0 in the prior quarter.
  • Over five years, Receivables - Other peaked at $688000.0 in Q1 2017 and troughed at $1000.0 in Q2 2014.
  • A 3-year average of $177250.0 and a median of $10000.0 in 2013 define the central range for Receivables - Other.